Tizanidine
| Evidence Level: L2 | Predicted Indications: 5 |
Table of Contents
Tizanidine: Migraine disorder
One-Sentence Summary
Tizanidine is a centrally acting alpha-2 adrenergic agonist marketed in Canada. The TxGNN model predicts it may be useful for migraine disorder, supported by 2 registered trials (one Phase 3 trial with no reported results) and 16 publications, including one placebo-controlled randomized trial in chronic daily headache. Evidence level: L2.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9979 |
| Evidence Level | L2 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Tizanidine is known as a central alpha-2 adrenergic agonist. By reducing the release of excitatory neurotransmitters, it is thought to dampen trigeminal pain transmission and central sensitization, which are plausible targets for migraine prevention.
Reviews of headache prophylaxis discuss tizanidine alongside other agents used for chronic migraine and chronic daily headache. Its effect on muscle tone and tension is also relevant to headache disorders with a muscular component.
Caveats: the best randomized evidence (PMID 12167135, 2002) studied chronic daily headache, a group that includes chronic migraine, migrainous headache and tension-type headache, rather than migraine alone. The Phase 3 migraine trial has no verified results.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05484349 | Phase 3 | Unknown | 189 | Multicenter, randomized, double-blind, placebo-controlled study of oral tizanidine for preventing attacks in adults with episodic migraine; no results available |
| NCT02403687 | N/A | Completed | 300 | 24-week observational study of topical NSAIDs for pain; only weak indirect relevance |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12167135 | 2002 | RCT | Headache | Double-blind, placebo-controlled multicenter study of tizanidine as adjunctive prophylaxis in chronic daily headache (including chronic migraine) |
| 11318882 | 2001 | Open-label study | Headache | Dose-titration study of tizanidine tablets for chronic daily headache prophylaxis |
| 11903539 | 2002 | Clinical study | Headache | Low-dose tizanidine with NSAIDs for detoxification from analgesic rebound headache |
| 20464578 | 2010 | Review | Neurol Sci | Review of double-blind placebo-controlled trials of chronic migraine prophylaxis |
| 12696998 | 2003 | Review | CNS Drugs | Muscle-tone agents (baclofen, tizanidine, botulinum toxin) as preventive treatment for migraine and tension-type headache |
| 31365643 | 2019 | Consensus guideline | Arq Neuropsiquiatr | Brazilian Headache Society consensus on chronic migraine treatment |
| 15115635 | 2004 | Review | Curr Pain Headache Rep | Emerging migraine prophylaxis options, including tizanidine |
| 40983294 | 2025 | Preclinical study | J Control Release | Tizanidine–meloxicam supramolecular self-assembly with enhanced anti-migraine efficacy |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02536765 | MINT-TIZANIDINE | Not stated | Not stated |
| 02259893 | APO-TIZANIDINE | Not stated | Not stated |
Safety Considerations
- Drug Interactions: 100 interactions were found. Major-level examples include famotidine, cimetidine, morphine, dolasetron and obeticholic acid. Moderate-level examples include hyoscyamine, loperamide, atropine, clarithromycin and levofloxacin. Known risks to manage include sedation, hypotension, liver toxicity and CYP1A2 inhibitors such as fluvoxamine and ciprofloxacin.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: One placebo-controlled randomized trial in chronic daily headache (mostly migraine patients) and a Phase 3 migraine prevention trial support the direction, but the Phase 3 trial has no results and there is only one randomized study. The evidence level is L2.
To proceed, the following is needed:
- Results of the Phase 3 migraine prevention trial (NCT05484349)
- Package insert warnings and contraindications for Canadian products
- Mechanism-of-action data
- A plan to manage sedation, hypotension, liver monitoring and CYP1A2 interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.